Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Is subcutaneous insulin administration adequate for the management of hyperglycemic crisis in COVID-19?

ABSTRACT

There is a desperate need to explore different insulin administration strategies, particularly in coronavirus disease 2019 (COVID-19) patients with hyperglycemic crisis. Noteworthily, diabetes mellitus (DM) and poorly controlled blood glucose increase the risk of mortality and severity of COVID-19. Intravenous (IV) insulin administration with hourly monitoring of blood glucose is the ideal approach in managing patients with hyperglycemic crisis, but it is not judicious to be applied in developing countries where shortage of personal protective equipment (PPE) is a major issue. Furthermore, increasing the probability of “already greater risks” for doctors or other healthcare workers contracting COVID-19 seems inappropriate. Thus, an alternative administration strategy and more moderate glucose monitoring to reduce the contact exposure of healthcare workers with COVID-19 patients, by ensuring appropriate blood glucose levels, needs to be performed in this critical pandemic era. Subcutaneous (SC) rapid-acting insulin analog administration could presumably be a solution to this contentious issue.

© 2020 Published by Elsevier Ltd on behalf of Diabetes India.

To the Editor,

We read an article by Singh et al. with immense interest [1] and agree with the authors that there is a desperate need to explore different insulin administration strategies, particularly in coronavirus disease 2019 (COVID-19) patients with hyperglycemic crisis. Noteworthily, diabetes mellitus (DM) and poorly controlled blood glucose [2,3], along with other comorbidities [4–6], increase the risk of mortality and severity of COVID-19. Although practical recommendations for managing DM in COVID-19 are presently available [7,8], they do not specifically address the management of hyperglycemic crisis in COVID-19. Intravenous (IV) insulin administration with hourly monitoring of blood glucose is the ideal approach in managing patients with hyperglycemic crisis, but it is not judicious to be applied in developing countries where shortage of personal protective equipment (PPE) is a major issue [9]. Furthermore, increasing the probability of “already greater risks” for doctors or other healthcare workers contracting COVID-19 seems inappropriate [10,11]. Thus, an alternative administration strategy and more moderate glucose monitoring to reduce the contact exposure of healthcare workers with COVID-19 patients, by ensuring appropriate blood glucose levels, needs to be performed in this critical pandemic era.

Subcutaneous (SC) rapid-acting insulin analog administration could presumably be a solution to this contentious issue. Although no specific evidence is available for comparing the SC rapid-acting insulin analogs and IV infusion of regular insulin approaches in managing hyperglycemic crisis in COVID-19 patients, both approaches are comparable in similar settings [12,13]. A systematic review of five randomized controlled trials (four in adults and one in younger participants and children) in patients with mild to moderate diabetic ketoacidosis (DKA) revealed no significant differences in mortality, time to resolution of DKA, mean length of hospital stay, and episodes of hypoglycemia [12]. Moreover, administration of SC rapid-acting insulin aspart presented better results than those of IV infusion of regular insulin in treating moderate DKA in pediatric patients with respect to faster/shorter hospital stay [13]. Nevertheless, in one retrospective cohort study [14], SC rapid-acting insulin analog was associated with higher hypoglycemic episodes and inefficient glucose control than IV insulin, although with comparable mortality rates. Although the use of SC rapid-acting insulin analog in managing this scenario remains controversial, it is in accordance with the Association of British Clinical Diabetologists (ABCD) guideline in managing DKA of COVID-19 [15]; a 4-h SC dose of rapid-acting insulin analog with an initial dose of 0.4 unit/kg with 2–4-h blood glucose monitoring seems to be a sensible alternative approach. This specific issue should be added among the unanswered research questions [16], yet it needs to be solved during this pandemic.

Funding

None.

Declaration of competing interest

None to declare.
References

[1] Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr Clin Res Rev 2020;14:303–10. https://doi.org/10.1016/j.dsx.2020.04.004.

[2] Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020;1–10. https://doi.org/10.1016/j.cmet.2020.04.021.

[3] Singh AK, Singh R. Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19? Diabetes Metab Syndr Clin Res Rev 2020;14:725–7. https://doi.org/10.1016/j.dsx.2020.05.037.

[4] Pranata R, Soeroto AY, Huang I, Lim MA, Santoso P, Pernama H, et al. Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19. Int J Tubercul Lung Dis 2020. https://doi.org/10.5588/ijtlld.20.0278.

[5] Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19—systematic review, meta-analysis, and meta-regression. J Stroke Cerebrovasc Dis 2020;29:104949. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104949.

[6] Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renn-Angiotensin-Aldosterone Syst JRAAS 2020;21. https://doi.org/10.1177/147032020926899. 147032020926899.

[7] Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020;8:546–50. https://doi.org/10.1016/S2213-8587(20)30152-2.

[8] Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr Clin Res Rev 2020;14:211–2. https://doi.org/10.1016/j.dsx.2020.03.002.

[9] Park C-Y, Kim K, Roth S, Beck S, Kang JW, Tayag MC, et al. Global shortage of personal protective equipment amid COVID-19: supply chains, bottlenecks, and policy implications. 2020. https://doi.org/10.22617/BRF200128-2. Manila, Philippines.

[10] Misra A. Doctors and healthcare workers at frontline of COVID 19 epidemic: admiration, a pat on the back, and need for extreme caution. Diabetes Metab Syndr Clin Res Rev 2020;14:255–6. https://doi.org/10.1016/j.dsx.2020.03.006.

[11] Chou R, Dana T, Buckley DI, Selph S, Fu R, Totten AM. Epidemiology of and risk factors for coronavirus infection in health care workers. Ann Intern Med 2020;M20–1632. https://doi.org/10.7326/M20-1632.

[12] Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Gonzalez-Padilla DA. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. Cochrane Database Syst Rev 2016;2016:C001281. https://doi.org/10.1002/14651858.CD0011281.pub2.

[13] Razavi Z, Maher S, Fredmal J. Comparison of subcutaneous insulin aspart and intravenous regular insulin for the treatment of mild and moderate diabetic ketoacidosis in pediatric patients. Endocrine 2018;S1:267–74. https://doi.org/10.1007/s12020-018-1635-z.

[14] Tran KK, Kibert JL, Telford ED, Franck AJ. Intravenous insulin infusion protocol compared with subcutaneous insulin for the management of hyperglycemia in critically ill adults. Ann Pharmacother 2019;53:894–8. https://doi.org/10.1177/1060028019841363.

[15] National Inpatient Diabetes Covid-19 Response Group. Concise adVice on inpatient diabetes (COVID:diabetes): guideline for managing DKA using subcutaneous, Insulin 2020:4–6.

[16] Gupta R, Hussain A, Misra A. Diabetes and COVID-19: evidence, current status and unanswered research questions. Eur J Clin Nutr 2020. https://doi.org/10.1038/s41430-020-0652-1.